Status: Recruiting
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Participants needed: 439
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: Curium US LLCUpdated: Jun 4, 2026Locations: 44
Eligibility criteria
Patients with histologically proven prostate adenocarcinoma. [+4]
Androgen deprivation therapy, neoadjuvant chemotherapy, radiation therapy (inclu... [+6]